Lactiplantibacillus sp. LP03 alleviates pulmonary fibrosis by modulating gut microbiota and elevating host palmitoylethanolamide to suppress TGF-β1/Smad2/3-mediated EMT
These findings highlight LP03 as a promising probiotic candidate for pulmonary fibrosis therapy. Its therapeutic effects are mediated by remodeling of the gut microbiota and elevation of systemic PEA, which in turn regulates fibrotic signaling pathways.
Authors
- Mei-Na Duan
- Yuhao Zhou (ORCID: https://orcid.org/0000-0002-0237-5813)
- Yang Zhao (ORCID: https://orcid.org/0000-0003-2338-5671)
- Chao Wang (ORCID: https://orcid.org/0009-0009-5719-3628)
- Tingting Wang (ORCID: https://orcid.org/0000-0002-4111-7913)
- Xiaoye Fan (ORCID: https://orcid.org/0009-0001-0739-1978)
- Shucheng Hua (ORCID: https://orcid.org/0000-0003-4349-746X)
Institutions
- Jilin University (CN)
- First Hospital of Jilin University (CN)
- Central Hospital of Zibo (CN)
Publication Details
- Journal
- Frontiers in Microbiology
- Published
- 2025-09-09
- DOI
- https://doi.org/10.3389/fmicb.2025.1659142
- Citations
- 1
- Primary Topic
- Gut microbiota and health
- Type
- article
- Field-Weighted Citation Impact
- 0.81